相关实验视频

Updated: Jul 2, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

基于TRiP ((cast) 评分的针对性预防性抗凝药:多中心,分阶,随机实施试验

Delphine Douillet¹, Andrea Penaloza², Damien Viglino³

¹Emergency Department, Health Faculty, Angers University Hospital, Angers, France; UMR MitoVasc CNRS 6015 - INSERM 1083, Equipe CARME, UNIV Angers, Angers, France; F-CRIN INNOVTE Network, Saint-Etienne, France.

Lancet (London, England)

|February 18, 2024

概括

低血栓风险预测值的下肢受伤患者不服用抗凝药是安全的. 这种方法在大量患者中显著减少了不必要的血栓预防.

科学领域:

紧急医疗
血管外科手术
临床血栓形成

背景情况:

对于需要固定下肢创伤的急诊室患者, 预防性抗凝药仍然是一个临床挑战.
造不动症患者的血栓形成风险预测 (TRiP) 评分旨在确定低风险患者.
本研究基于TRiP (造) 评分来评估保留抗凝药的安全性.

研究的目的:

预期评估在下肢受伤和不动化的患者中保留预防性抗凝剂的安全性.
确定 TRiP ((cast) 分数低于7是否确定静脉血栓塞栓症 (VTE) 的低风险组.

主要方法:

一个分阶段,多中心,随机集群试验 (CASTING) 涉及15个急救部门.
包括下肢受伤需要至少7天的固定治疗的患者.
主要结局是TRiP (射) 评分< 7的患者的3个月累计VTE发生率,目标安全值为< 1% (上95% CI< 2%).

主要成果:

在没有接受抗凝血治疗的TRiP ((cast) 评分< 7的患者中,症状性静脉瘤发生率为0. 7% (95% CI为0. 3 - 1. 4).
这一比例低于预先定义的安全门.
在对照阶段和干预阶段之间没有观察到静脉突发症或出血率的显著差异.

结论:

患有下肢创伤和动不动的患者,TRiP (造) 评分< 7的风险非常低.
很大一部分患者可以安全地避免血栓预防,从而优化治疗策略.

更多相关视频

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.